NasdaqCM:TGTXBiotechs
Is Briumvi-Driven Earnings Growth Altering The Investment Case For TG Therapeutics (TGTX)?
TG Therapeutics, Inc. has reported its first-quarter 2026 results, with revenue rising to US$204,920,000 from US$120,860,000 a year earlier and net income increasing to US$19,780,000 from US$5,060,000, lifting basic earnings per share from continuing operations to US$0.14 and diluted earnings per share to US$0.12.
The strong quarterly performance underscores ongoing traction for Briumvi in multiple sclerosis and sets the backdrop for the company’s planned subcutaneous formulation launch,...